Regeneron (REGN) Gets FDA Priority Review, EMA Acceptance for Cemdisiran

Regeneron Pharmaceuticals (NasdaqGS:REGN) announced that the U.S. Food and Drug Administration (FDA) has accepted its application for Priority Review of cemdisiran for the treatment of generalized myasthenia gravis (gMG). The European Medicines Agency (EMA) has also accepted the marketing application for the same drug, aligning regulatory review across the Atlantic.

Details of the Action

• FDA: Granted Priority Review for the cemdisiran Biologics License Application (BLA), which shortens the review period to 6 months from the standard 10 months.
• EMA: Accepted the marketing authorization application (MAA), allowing parallel review.
• Clinical Data: Phase 3 trial results for cemdisiran were published in The Lancet, providing peer-reviewed clinical evidence.

Company's Position

Regeneron believes cemdisiran has the potential to offer a new treatment option for patients with generalized myasthenia gravis, a rare autoimmune disease causing muscle weakness.

Precedents and Context

Generalized myasthenia gravis is a chronic condition affecting nerve-muscle communication. Current treatments include cholinesterase inhibitors and immunosuppressive therapies. If approved, cemdisiran would be the first siRNA therapy for this disease.

Potential Financial Impact

Regeneron has not provided specific financial guidance. The stock is currently trading at $654.27. Approval could add a meaningful product to Regeneron's pipeline, though market size remains uncertain.